How does losartan work
Pro Research Analysisby 
Searched over 200M research papers
Mechanism of Action of Losartan
Angiotensin II Receptor Antagonism
Losartan is primarily known for its role as an angiotensin II type 1 (AT1) receptor antagonist. By blocking the AT1 receptor, losartan inhibits the effects of angiotensin II, a potent vasoconstrictor involved in the regulation of blood pressure and fluid balance. This blockade leads to vasodilation, reduced secretion of vasopressin, and decreased production and release of aldosterone, which collectively contribute to lowering blood pressure .
Impact on the Renin-Angiotensin System (RAS)
Losartan's inhibition of the AT1 receptor disrupts the renin-angiotensin system (RAS), which plays a crucial role in cardiovascular and renal physiology. By preventing angiotensin II from binding to its receptor, losartan reduces the downstream effects of this pathway, including vasoconstriction and sodium retention. This mechanism is particularly beneficial in managing conditions like hypertension and diabetic nephropathy .
Antioxidant Properties
Research has shown that losartan also possesses antioxidant properties. In studies involving apolipoprotein E-deficient mice, losartan was found to inhibit low-density lipoprotein (LDL) lipid peroxidation, which is a key factor in the development of atherosclerosis. This effect was demonstrated by a significant reduction in malondialdehyde content in LDL and a prolonged lag time for LDL oxidation, ultimately leading to a reduction in atherosclerotic lesion areas.
Renal Protection
Losartan has been extensively studied for its renal protective effects, especially in patients with type 2 diabetes and nephropathy. Clinical trials have shown that losartan significantly reduces the incidence of doubling of serum creatinine levels, end-stage renal disease (ESRD), and proteinuria. These benefits are attributed to its ability to lower intraglomerular pressure and reduce proteinuria, thereby slowing the progression of renal disease .
Endothelial Function Improvement
In patients with non-insulin-dependent diabetes mellitus (NIDDM), losartan has been shown to improve endothelial function. This improvement is likely due to the blockade of the AT1 receptor, which enhances endothelium-dependent vasodilation. Studies have demonstrated that losartan administration leads to a significant decrease in vascular resistance and an increase in forearm blood flow in response to acetylcholine, indicating better endothelial function.
Pharmacokinetics and Metabolism
Losartan is rapidly absorbed after oral administration, reaching peak plasma concentrations within 1-2 hours. Approximately 14% of losartan is converted to its active metabolite, EXP3174, which is significantly more potent than the parent compound. The drug is metabolized primarily by the cytochrome P450 enzymes CYP3A4 and CYP2C9. Losartan and its metabolite have a favorable pharmacokinetic profile, with linear and dose-proportional kinetics, and are well-tolerated across different patient populations .
Anti-Inflammatory Effects
Recent studies have also highlighted losartan's potential anti-inflammatory effects. In models of acute lung injury induced by seawater inhalation, losartan was shown to alleviate lung injury by inhibiting the combination of angiotensin II and the AT1 receptor. This inhibition led to decreased activation of inflammatory pathways such as NF-κB and JAK2/STATs, and reduced apoptosis in lung cells.
Conclusion
Losartan is a multifaceted drug that exerts its therapeutic effects primarily through the antagonism of the AT1 receptor, leading to significant benefits in blood pressure regulation, renal protection, and endothelial function. Its antioxidant and anti-inflammatory properties further enhance its clinical utility, making it a valuable treatment option for various cardiovascular and renal conditions.
Sources and full results
Most relevant research papers on this topic